Quintiles IMS Holdings Inc (Q)

93.22
1.70 1.80
NYSE : Health Care
Prev Close 91.55
Open 91.55
Day Low/High 91.55 / 93.08
52 Wk Low/High 70.10 / 93.53
Volume 1.15M
Avg Volume 1.03M
Exchange NYSE
Shares Outstanding 216.53M
Market Cap 19.82B
EPS 0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

QuintilesIMS To Announce Second-Quarter 2017 Results On August 3, 2017

QuintilesIMS To Announce Second-Quarter 2017 Results On August 3, 2017

Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE:Q) will announce its second-quarter 2017 financial results before the market opens on Thursday, August 3, 2017.

Short Interest In Quintiles IMS Holdings Drops 13.7%

Short Interest In Quintiles IMS Holdings Drops 13.7%

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,412,114 share decrease in total short interest for Quintiles IMS Holdings Inc , to 8,907,498, a decrease of 13.68% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Quintiles IMS Holdings Larger Than S&P 500 Component Nucor Corp.

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Quintiles IMS Holdings Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Nucor Corp. , according to The Online Investor.

QuintilesIMS Introduces Orchestrated Customer Engagement (OCE)

QuintilesIMS (NYSE:Q), a leading provider of information, technology services and contract research to the life sciences industry announced today the general availability of a new category of pharmaceuticals commercial...

QuintilesIMS To Participate In William Blair Growth Stock Conference On June 14, 2017

Quintiles IMS Holdings, Inc. (NYSE:Q), a leading global provider of information, technology services and contract research to the healthcare and life sciences industries, announced today that Mike McDonnell, executive vice...

QuintilesIMS Institute Study: New Class Of Oncology Therapies Provides More Options, Better Outcomes Than Any Point In History

During the past decade, advances in personalized medicine and immuno-oncology have fueled a major shift in treatment of cancer.

QuintilesIMS Announces Pricing Of Secondary Public Offering

Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE:Q) announced today the pricing of an underwritten, secondary public offering of 10,571,003 shares of its common stock by certain of its existing stockholders, including...

QuintilesIMS Announces Launch Of Secondary Public Offering, Repurchase Of Common Stock And Increase In Share Buyback Authorization

Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE: Q) announced today the launch of an underwritten, secondary public offering of 10,571,003 shares of its common stock by certain of its existing stockholders, including...

QuintilesIMS Reports First-Quarter 2017 Results And Raises Full-Year 2017 Adjusted Diluted EPS Guidance

Quintiles IMS Holdings, Inc. (NYSE: Q), a leading global provider of information, technology services and contract research to the healthcare and life sciences industries, today reported financial results for the quarter...

QuintilesIMS Announces Alliance With Salesforce To Build Next Generation Solutions For Life Sciences Firms — From Molecule To Market

QuintilesIMS (NYSE:Q), a leading provider of information, technology services and contract research to the life sciences industry, today announced an alliance with Salesforce, the world's #1 CRM company and Intelligent...

QuintilesIMS To Announce First-Quarter 2017 Results On May 3, 2017

Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE: Q) will announce its first-quarter 2017 financial results before the market opens on Wednesday, May 3, 2017.

Parexel Is Discovering the Drugs of the Future

Parexel Is Discovering the Drugs of the Future

The midcap drug maker is finding growth as an outsourcing destination.

QuintilesIMS Announces Pricing Of Senior Notes

Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE: Q) today announced the pricing of the offering of €1.

QuintilesIMS Announces Offering Of Senior Notes And Proposed Refinancing Of Existing Indebtedness

Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE: Q) today announced that its wholly owned subsidiary, Quintiles IMS Incorporated (the "Issuer"), intends to raise €850 million in gross proceeds through an offering...

Analysts' Actions -- Arista, Capital One, Avis, Workday and More

Analysts' Actions -- Arista, Capital One, Avis, Workday and More

Here are Friday's top research calls, including upgrades for Arista Networks, Capital One Financial and Workday, and a downgrade for Avis Budget.

QuintilesIMS Named To FORTUNE's 2017 List Of "World's Most Admired Companies"

QuintilesIMS has once again been named to FORTUNE magazine's "World's Most Admired Companies" list.

QuintilesIMS Reports Fourth-Quarter And Full-Year 2016 Results, Issues First-Quarter And Full-Year 2017 Guidance

Quintiles IMS Holdings, Inc. (NYSE:Q), a leading global provider of information, technology services and contract research to the healthcare and life sciences industries, today reported financial results for the quarter and...

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More

Here are Friday's top research calls, including an upgrade for Ford and downgrades for Eaton, Altria and Ralph Lauren.

QuintilesIMS To Announce Fourth-Quarter 2016 Results And Issue 2017 Guidance On February 14, 2017

Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE:Q) will announce its fourth-quarter and full-year 2016 financial results and issue 2017 guidance before the market opens on Tuesday, February 14, 2017.

These 5 Health Care Stocks Are Breaking Out This Christmas

These 5 Health Care Stocks Are Breaking Out This Christmas

The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.

INC Research Holdings Seen as Likely LabCorp. Takeover Target

INC Research Holdings Seen as Likely LabCorp. Takeover Target

The contract research organization has been viewed as a logical takeout target of LabCorp. for some time now.

Merger Costs, Missed Deal Have Analysts Questioning Quintiles

Merger Costs, Missed Deal Have Analysts Questioning Quintiles

The biotech company's shares have increased about 12% this year, but a number of analysts have downgraded it over the past two months.

QuintilesIMS Institute Forecast: Global Drug Market Will Reach Nearly $1.5 Trillion In 2021 As Spending Growth Moderates

QuintilesIMS Institute Forecast: Global Drug Market Will Reach Nearly $1.5 Trillion In 2021 As Spending Growth Moderates

Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33 percent from 2016 levels, even as annual growth moderates from the record pace set in 2014 and 2015, according to new research released today by...

Analysts' Actions -- J.C. Penney, Lululemon, Square, Exxon and More

Analysts' Actions -- J.C. Penney, Lululemon, Square, Exxon and More

Here are Friday's top research calls, including upgrades for J.C. Penney and Square, a downgrade for Lululemon and new coverage on Exxon Mobil.

Analysts' Actions -- Alcoa, Cerner, Deere, Quintiles and More

Analysts' Actions -- Alcoa, Cerner, Deere, Quintiles and More

Here are Thursday's top research calls, including an upgrade for Deere, downgrades for Cerner and Quintiles, and new coverage of Alcoa.

QuintilesIMS Named Best Full-service Provider CRO In 2016 Scrip Awards

QuintilesIMS Named Best Full-service Provider CRO In 2016 Scrip Awards

QuintilesIMS has been recognized by the 2016 Scrip Awards as the Best Full-service Provider Contract Research Organization (CRO).

Paul Spreen, Executive Vice President And Chief Customer Officer, QuintilesIMS. (Photo: Business Wire)

Paul Spreen, Executive Vice President And Chief Customer Officer, QuintilesIMS. (Photo: Business Wire)

Quintiles IMS Holdings, Inc. (NYSE:Q) announced today the appointment of Richard Staub III, currently president of Novella Clinical, a Quintiles company, as well as the leader of QuintilesIMS's Global Functional Resourcing...